Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04813718Not ApplicableActive Not Recruiting

Post COVID-19 Syndrome and the Gut-lung Axis

Role: collaborator

NCT05836168Not ApplicableActive Not Recruiting

Effects of Microbiome Modulation on Sleep in Working People

Role: collaborator

NCT05737030Phase 4Active Not Recruiting

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

Role: collaborator

NCT05836155Not ApplicableActive Not Recruiting

Evidence Based Probiotic Therapy of Proton Pump Inhibitor Induced Dysbiosis

Role: collaborator

All 4 trials loaded